Abstract:Background Varicella-zoster virus (VZV) and herpes zoster cause infections of the central nervous system (CNS) manifesting as meningitis or encephalitis. As compared to enterovirus (EV) and herpes simplex virus 1 (HSV-1) and 2 (HSV-2), it is not often tested in CNS infections due to VZV and herpes zoster. There is a certain tendency to think that the findings in the cerebrospinal fluid in infections of the CNS by viruses are comparable among themselves. The exact proportion of patients with VZV primary and reactivation infection who present with lesions prior to or concomitant to its involvement in the CNS is unknown. It is also not known about the risk factors that lead to the reactivation of VZV and CNS involvement. Objective To describe the clinical characteristics and laboratory results of patients with a positive VZV polymerase chain reaction (PCR) and neurological signs and symptoms. Methods A retrospective and descriptive study was performed at the Hospital Universitario de la Pontificia Universidad Católica de Chile (Hospital Clínico UC CHRISTUS) from September 2012 to July 2014. The following parameters were recorded: neurological signs and symptoms, PCR for VZV in cerebrospinal fluid (CSF), comorbidities, personal medical history, cutaneous lesions, CSF characteristics, CNS imaging, electroencephalography (EEG), treatment, mortality, and neurological sequelae. Adult patients with meningitis, encephalitis, or meningoencephalitis due to VZV diagnosed with PCR were included. Results Out of 70 CSF samples analyzed in the previously mentioned period, 21 cases were VZV positive, 16 cases that had clinical information available were included. The mean age with VZV CNS reactivation was 47 years (range 19-80 years). Five patients (31.25%) were immunocompromised: three had human immunodeficiency virus (HIV), one had kidney transplantation, and one had primary immunodeficiency. Clinical presentation was meningitis in 11 patients (68.75%) and encephalitis in five patients (31.25%). Pleocytosis in CSF was observed in all the samples. The five immunocompromised patients had cutaneous lesions. All patients received antiviral treatment. Therapy duration was from 10 up to 21 days. The clinical course was positive in most patients and the mean hospitalization time was 15 days (range 5-60 days). No mortality was observed. Conclusions VZV is a worldwide virus and a common cause of CNS infection. The rising incidence is probably due to a better diagnostic method and a frequent clinical suspicion even in the absence of cutaneous lesions, except in immunocompromised cases, as it was observed in the present study. CNS infection presented as a wide spectrum of clinical manifestations with possible neurological sequelae. There was a reduction in neurological morbidity with antiviral therapy. Nonetheless, both the incidence and the morbidity of CNS VZV infection are expected to be diminished by varicella and herpes zoster vaccination. Additionally, there was no increase in mortality in these patients.

MR-Bildgebung der Varizella-Zoster-Virusinfektion im zentralen und peripheren Nervensystem – von Ramsay-Hunt bis Elsberg

Cerebrospinal Fluid Proteomics in Meningitis Patients with Reactivated Varicella Zoster Virus

Varicella-Zoster Virus Meningitis and Encephalitis: An Understated Cause of Central Nervous System Infections

The Role of Varicella Zoster Virus (VZV) in Central Nervous System Infectious Syndromes

Herpes Zoster bei entzündlich-rheumatischen Erkrankungen

Varicella-Zoster Disease of the Central Nervous System in Immunocompetent Children: Case Series and a Scoping Review

Clinical Features of Varicella-Zoster Virus Infection

Determinants of neurological syndromes caused by varicella zoster virus (VZV)

Acute myelitis with multicranial neuritis caused by Varicella zoster virus: a case report

Immunopatological and Genetic Aspects of the Pathogenesisof CNS Lesions in VZV Infection

Varicella zoster virus vasculopathy: The expanding clinical spectrum and pathogenesis

Serological Diagnosis and Molecular Detection of Varicella Zoster Virus in Patients with Suspected Meningoencephalitis

Varicella‐zoster virus‐related neurological complications: From infection to immunomodulatory therapies

Diagnostic value of anti-VZV IgG in neurological diseases among varicella unvaccinated individuals

Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections

Varicella Zoster Virus Vasculopathy

Central Nervous System Vasculopathy In Varicella Zoster Virus Infection

Quantitative real time PCR detection of Varicella-zoster virus DNA in cerebrospinal fluid in patients with neurological disease

Don't rash it! The Clinical Significance of Positive Varicella Zoster Virus PCR in Cerebrospinal Fluid of Patients with Neurological Symptoms

Varicella‑zoster virus‑associated meningitis followed peripheral facial palsy: A case report

Meningitis/meningoencephalitis Caused by Varicella Zoster Virus Reactivation: a Retrospective Single-Center Case Series Study.